The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of the OX40 agonist BGB-A445, in combination with docetaxel or BGB-15025, an HPK1 inhibitor, in patients with NSCLC pretreated by anti-PD-(L)1 antibodies.
 
Tae Min Kim
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Chong Kun Dang Pharmaceutical; Daiichi Sankyo/Astra Zeneca; inno.N; Janssen Oncology; Merck KGaA; Novartis; Regeneron; Roche; Samsung Bioepis; Takeda
Speakers' Bureau - Amgen; AstraZeneca/MedImmune; Janssen Research & Development; Takeda
(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boryung (Inst); Bristol Myers Squibb Foundation (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Dizal Pharma (Inst); Enliven Therapeutics (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); Hanmi (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); RAPT Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst); Yuhan (Inst)
 
Haiyan Liu
No Relationships to Disclose
 
Byoung Chul Cho
Employment - Yonsei University Health System
Leadership - J INTS BIO
Stock and Other Ownership Interests - Bridgebio; Cyrus therapeutics; Gencurix; Interpark Bio; J INTS BIO; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - Amgen; AnHeart Therapeutics; ArriVent Biopharma; AstraZeneca; BeiGene; BMS; Boehringer Ingelheim; Bridgebio; CJ bioscience; Cyrus therapeutics; Cyrus therapeutics; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Guardant Health; Harpoon Therapeutics; J INTS Bio; Janssen; Kanaph Therapeutics; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Regeneron; Roche; Sanofi; Seagen; Takeda; Therapex Co., Ltd; Yuhan
Research Funding - AstraZeneca; Champions Oncology; CJ bioscience; Cyrus Therapeutics; Dong-A ST; GI Innovation; ImmuneOncia; J Ints Bio; Janssen; MSD; Therapex; Vertical Bio AG; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology; Crown Bioscience; Imagen; PearlRiver Bio GmbH
Other Relationship - DAAN Biotherapeutics
 
Youngjoo Lee
Consulting or Advisory Role - MSD; Roche; Yuhan
 
Byoung Yong Shim
Consulting or Advisory Role - AstraZeneca; Guardant Health; J Ints Bio; Takeda
Research Funding - Yuhan
 
Fang Ma
No Relationships to Disclose
 
Mingjuan Zhang
No Relationships to Disclose
 
Jianchun Duan
No Relationships to Disclose
 
Hongling Li
No Relationships to Disclose
 
Ramil Abdrashitov
Employment - BeOne Medicines Ltd; Insmed (I)
Stock and Other Ownership Interests - AstraZeneca; AstraZeneca (I); BeOne Medicines Ltd; Geron; Revolution Medicines; Syndax; Takeda
 
Zhaoyin Zhu
Employment - BeOne Medicines Ltd
Stock and Other Ownership Interests - BeOne Medicines Ltd
 
Hugh Giovinazzo
Employment - BeOne Medicines Ltd
Stock and Other Ownership Interests - BeOne Medicines Ltd
 
Ye Zhao
Employment - BeOne Medicines Ltd
Stock and Other Ownership Interests - BeOne Medicines Ltd
 
Yajie Guo
Employment - BeOne Medicines Ltd
Stock and Other Ownership Interests - BeOne Medicines Ltd
 
Jie Wang
No Relationships to Disclose